General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam 1%

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
21-Sep-2021 13:48:37
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam 1%
Announcement Reference
SG210921OTHRL57R
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
21/09/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam 1%

Attachments

SGX_PR_21092021.pdf
Total size =660K